EPITHELIOID SARCOMA
Clinical trials for EPITHELIOID SARCOMA explained in plain language.
Never miss a new study
Get alerted when new EPITHELIOID SARCOMA trials appear
Sign up with your email to follow new studies for EPITHELIOID SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virus and immunotherapy team up against rare cancers
Disease control OngoingThis study tests whether combining a cancer-killing virus (T-VEC) with an immunotherapy drug (pembrolizumab) can shrink tumors in people with advanced sarcoma that cannot be removed by surgery. About 41 adults with certain sarcoma types will receive both drugs. The main goal is t…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like atypical teratoid/rhabdoid tumors or epithelioid sarcoma) have returned or not responded to treatment. These cancers lack certain genes, making them hard to tre…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:46 UTC
-
New combo therapy aims to shrink sarcomas before surgery
Disease control OngoingThis study looks at whether adding the drug pazopanib to standard radiation or chemoradiation helps shrink soft tissue sarcomas before they are removed surgically. About 140 adults and children with newly diagnosed, high-risk sarcomas that can be operated on are participating. Th…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for kids with rare cancers: Three-Drug combo under study
Disease control OngoingThis study tests a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—for children with rare tumors that lack certain proteins (INI1 or SMARCA4). The goal is to find safe doses and see if the drugs shrink tumors. About 49 children with specific cancers like atypic…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Susan Chi, MD • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Immunotherapy duo takes on rare childhood tumors
Disease control OngoingThis study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink or control rare INI1-negative cancers in children and young adults. These cancers have returned or not responded to standard treatments. The goal is to see if the drug combo helps the…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:48 UTC